Facility Design and Engineering

Grand River Aseptic Manufacturing Completes Phase II of Facility Expansion

August 22, 2022

Grand River Aseptic Manufacturing has completed phase II of its facility expansion with the installation of two new sterile filling lines.

Overcoming Engineering Challenges to Enable Commercial Scale mRNA Vaccine Manufacturing

August 03, 2022

This article provides an overview of solutions to address key challenges facing vaccine developers or CDMOs wishing to build their own commercial-scale mRNA production facilities.

TFF Pharmaceuticals Expands R&D Operations with New Facility

July 19, 2022

TFF Pharmaceuticals is expanding its R&D operations with a new facility in Austin, Texas.

Wacker Biotech Expands Germany Site with Construction of New mRNA Competence Center

July 12, 2022

Wacker is investing more than €100 million (US$100.5 million) to expand its Halle, Germany, site with an mRNA competence center.

REGENXBIO Launches New Gene Therapy Manufacturing Facility in US

June 13, 2022

REGENXBIO has opened a new in-house facility at its headquarters in Rockville, Md., that will be used to manufacture AAV gene therapies at commercial scale.

Astellas Opens New US-based Large-Scale Gene Therapy Manufacturing Facility

June 10, 2022

Astellas Pharma has opened its new gene therapy manufacturing facility in Sanford, NC, which will support clinical- and commercial-scale manufacturing of AAV vectors for gene therapies.

Seqirus Announces Completion of $156 Million Expansion of Vaccine Manufacturing Facility

June 10, 2022

The expansion at Seqirus’ Holly Springs, N.C., manufacturing facility will support the formulation and fill/finish of influenza vaccines.

AGC Biologics Adds Viral Vector Suspension Technology at New US Campus

May 26, 2022

AGC Biologics is investing in viral vector suspension technology at its new Longmont, Colo., facility.

Thermo Fisher Scientific Expands R&D Facility in Hyderabad

April 28, 2022

Thermo Fisher Scientific has expanded its state-of-the-art R&D facility in Hyderabad, India.

Catalent to Invest $350 Million in Manufacturing Facility in Bloomington, Indiana

April 22, 2022

Catalent will invest $350 million into integrated biologics drug substance and drug product manufacturing at Bloomington, Indiana facility.